KROS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Keros Therapeutics Inc (KROS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive catalysts, weak financial performance, and neutral trading trends suggest holding off on investment until clearer growth signals emerge.
The MACD is positive but contracting, RSI is neutral at 52.167, and moving averages are converging, indicating no strong trend. Key support is at 11.046, and resistance is at 12.47. The stock is trading near its pivot point of 11.758.
NULL identified. No recent news or significant trading trends. Analysts maintain an Overweight rating but expect bearish sentiment in the near term.
Revenue dropped significantly by -87.34% YoY in Q4 2025, with net income down -49.03% YoY. EPS also declined by -23.68%. No recent congress trading data or influential figure activity.
In Q4 2025, revenue dropped to $385,000 (-87.34% YoY), net income fell to -$23.46M (-49.03% YoY), and EPS decreased to -0.87 (-23.68% YoY). Gross margin remained at 100%.
Wells Fargo lowered the price target to $20 from $23 while maintaining an Overweight rating. The firm anticipates bearish sentiment in the near term but sees potential in long-term data from rinvatercept, with key readouts expected in 2027.
